Human CCL26/Eotaxin-3 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB653
Key Product Details
Validated by
Biological Validation
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
ELISA Capture (Matched Antibody Pair), Neutralization, Western Blot
Cited:
ELISA Development, Immunocytochemistry, Immunohistochemistry-Paraffin
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 115002
Product Specifications
Immunogen
E. coli-derived recombinant human CCL26/Eotaxin-3
Thr24-Leu94
Accession # Q9Y258
Thr24-Leu94
Accession # Q9Y258
Specificity
Detects human CCL26/Eotaxin-3 in ELISAs and Western blots. Does not cross-react with recombinant human (rh) CCL11/Eotaxin, recombinant mouse (rm) CCL11/Eotaxin, rhCCL24/Eotaxin-2, rmCCL24/Eotaxin-2, rhCCL3, rhCCL4, rmCCL3, rmCCL4, rhCCL5, rhCCL13, or rhCCL14.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human CCL26/Eotaxin-3 Antibody
Detection of Human CCL26/Eotaxin‑3 by Western Blot.
Western blot shows lysates of HUVEC human umbilical vein endothelial cells untreated (-) or treated (+) with 100 U/mL Recombinant Human IL-4 (Catalog # 204-IL) for 24 hours. PVDF membrane was probed with 2 µg/mL of Mouse Anti-Human CCL26/Eotaxin-3 Monoclonal Antibody (Catalog # MAB653) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for CCL26/ Eotaxin-3 at approximately 12 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
Chemotaxis Induced by CCL26/Eotaxin-3 and Neutralization by Human CCL26/Eotaxin-3 Antibody.
Recombinant Human CCL26/Eotaxin-3 (Catalog # 346-E3) chemoattracts the BaF3 mouse pro-B cell line transfected with mouse CCR3 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL26/Eotaxin-3 (1 µg/mL) is neutralized (green line) by increasing concentrations of Human CCL26/Eotaxin-3 Monoclonal Antibody (Catalog # MAB653). The ND50 is typically 2-8 µg/mL.Applications for Human CCL26/Eotaxin-3 Antibody
Application
Recommended Usage
Western Blot
2 µg/mL
Sample: HUVEC human umbilical vein endothelial cells treated with Recombinant Human IL‑4 (Catalog # 204-IL)
Sample: HUVEC human umbilical vein endothelial cells treated with Recombinant Human IL‑4 (Catalog # 204-IL)
Neutralization
Measured by its ability to neutralize CCL26/Eotaxin-3-induced chemotaxis in the BaF3 mouse pro-B cell line transfected with mouse CCR3. The Neutralization Dose (ND50) is typically 2-8 µg/mL in the presence of 1 µg/mL Recombinant Human CCL26/Eotaxin-3.
Human CCL26/Eotaxin-3 Sandwich Immunoassay
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Reviewed Applications
Read 1 review rated 5 using MAB653 in the following applications:
Formulation, Preparation, and Storage
Purification
Protein A or G purified from ascites
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CCL26/Eotaxin-3
Additional CCL26/Eotaxin-3 Products
Product Documents for Human CCL26/Eotaxin-3 Antibody
Product Specific Notices for Human CCL26/Eotaxin-3 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...